GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Equity-to-Asset

Myriad Genetics (Myriad Genetics) Equity-to-Asset

: 0.68 (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Myriad Genetics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $783.2 Mil. Myriad Genetics's Total Assets for the quarter that ended in Dec. 2023 was $1,146.5 Mil. Therefore, Myriad Genetics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.68.

The historical rank and industry rank for Myriad Genetics's Equity-to-Asset or its related term are showing as below:

MYGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.64   Med: 0.74   Max: 0.87
Current: 0.68

During the past 13 years, the highest Equity to Asset Ratio of Myriad Genetics was 0.87. The lowest was 0.64. And the median was 0.74.

MYGN's Equity-to-Asset is ranked better than
57.74% of 239 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59 vs MYGN: 0.68

Myriad Genetics Equity-to-Asset Historical Data

The historical data trend for Myriad Genetics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.65 0.73 0.74 0.68

Myriad Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.71 0.62 0.60 0.68

Competitive Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics Equity-to-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Equity-to-Asset falls into.



Myriad Genetics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Myriad Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=783.2/1146.5
=0.68

Myriad Genetics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=783.2/1146.5
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myriad Genetics  (NAS:MYGN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Myriad Genetics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (Myriad Genetics) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart officer: Executive VP Human Resources 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury officer: Senior V.P. - Research 320 WAKARA WAY, SALT LAKE CITY UT 84108